B. Riley Securities Rates Kymera Therapeutics (KYMR) buy
B. Riley Securities has reaffirmed its buy rating on Kymera Therapeutics with a new price target of $155, a 35.17% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B. Riley Securities rated Kymera Therapeutics, Inc. ($KYMR) "buy" with a $155 price target on June 29, 2026.
Since the rating, $KYMR is up 5.0% after 1 week, down 3.7% after 1 month and down 4.2% to date (from the $109.32 close on Jun 29, 2026).
KYMR
Kymera Therapeutics, Inc.
Key Points
- B. Riley Securities reiterated its buy rating on Kymera Therapeutics, raising the price target from $135 to $155 on June 29, 2026.
- Kymera Therapeutics is currently trading at $114.67, well below the new target, suggesting significant upside potential.
- The stock has a market cap of approximately $9.68 billion and is involved in developing therapeutics for various conditions, including atopic dermatitis.
Get $KYMR trade alerts by text
We text you when insiders, Congress or big funds trade $KYMR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Kymera Therapeutics, Inc. alert may contain errors. Disclosures
Analysts Set New Price Targets
On June 29, 2026, B. Riley Securities reiterated its buy rating on Kymera Therapeutics, Inc. (NasdaqGM: KYMR) and raised its price target to $155. The stock was trading at $114.67 at the time of the announcement, reflecting a potential upside for investors based on the target price.
B. Riley Securities vs. the S&P 500
Hypothetical returns from B. Riley Securities's disclosed trades, not real profit or advice. How we model this.
Institutional Context
No additional institutional activity was reported alongside this rating change.
How Kymera Therapeutics, Inc. Stock Has Traded
Kymera Therapeutics is currently priced at $114.67, which is below its new price target of $155. This suggests that the stock may have room to grow, especially considering its recent trading history near a 52-week high of $130.05 and a low of $50.35. The stock's performance is worth noting as it has been fluctuating around its 50-day moving average of $114.36.
$KYMR price target
Kymera Therapeutics, Inc. daily closes and this analyst's $155 target. Not advice.
Recent Earnings
In its most recent earnings report, Kymera Therapeutics reported revenue of $105 million, showing a growth of about 4.7% year-over-year. The company has a negative EPS of -3.25 and a net margin of -2.85%. The next earnings report is expected on November 3, 2026.
What Kymera Therapeutics, Inc. Does
Kymera Therapeutics, based in Watertown, Massachusetts, focuses on developing small molecule therapeutics that target and degrade disease-causing proteins. The company is actively engaged in clinical trials for several treatments, including those for atopic dermatitis and autoimmune diseases.
What's Ahead for Kymera Therapeutics, Inc.
Investors should keep an eye on the upcoming earnings report scheduled for November 3, 2026. This reiteration from B. Riley Securities highlights the firm’s confidence in Kymera's potential, especially as it continues to work on promising therapeutics.
Related Filing Alerts
Source: B. Riley Securities's rating change on $KYMR (Jun 29, 2026). Written by software, not financial advice. How we make alerts